Anavex Life Sciences (AVXL) Total Non-Current Liabilities (2012 - 2014)
Anavex Life Sciences recorded quarterly Total Non-Current Liabilities of $1.9 million in Q2 2014, up 1.11% quarter-over-quarter from $1.9 million in Q1 2014.
Anavex Life Sciences' Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $1.9 million for Q2 2014.
- In Q2 2014, Total Non-Current Liabilities changed N/A year-over-year to $1.9 million; the TTM figure through Jun 2014 stood at $1.9 million (changed N/A YoY), while the FY2013 annual figure was $2.0 million, down 32.39% from the prior year.
- Total Non-Current Liabilities came in at $1.9 million for Q2 2014 at Anavex Life Sciences, up from $1.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $2.9 million in Q3 2012 to a low of $1.8 million in Q4 2013.
- A 3-year average of $2.1 million and a median of $1.9 million in 2014 frame the typical range for Total Non-Current Liabilities.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 32.39% in 2013 and fell as far as 32.39% in 2013.
- Anavex Life Sciences' Total Non-Current Liabilities stood at $2.9 million in 2012, then tumbled by 36.95% to $1.8 million in 2013, then gained by 4.62% to $1.9 million in 2014.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.9 million, $1.9 million, and $1.8 million for Q2 2014, Q1 2014, and Q4 2013 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 1.91 Mn |
| Mar 31, 2014 | 1.88 Mn |
| Dec 31, 2013 | 1.82 Mn |
| Sep 30, 2013 | 1.95 Mn |
| Sep 30, 2012 | 2.89 Mn |